Stay updated on Immune Checkpoint vs Target Therapy for HBsAg+ HCC Clinical Trial
Sign up to get notified when there's something new on the Immune Checkpoint vs Target Therapy for HBsAg+ HCC Clinical Trial page.

Latest updates to the Immune Checkpoint vs Target Therapy for HBsAg+ HCC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.9%
- Check18 days agoNo Change Detected
- Check26 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check33 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check61 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check76 days agoChange DetectedThe webpage has been updated to include new drug names, Regorafenib and Cabozantinib, in the context of a clinical trial for Hepatocellular Carcinoma (HCC), while significant background information about HCC and its relation to HBV has been removed.SummaryDifference47%
- Check83 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to March 24, 2025.SummaryDifference0.2%
Stay in the know with updates to Immune Checkpoint vs Target Therapy for HBsAg+ HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Immune Checkpoint vs Target Therapy for HBsAg+ HCC Clinical Trial page.